30 closest matches · ranked by relevance
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants
Peripheral T-cell Lymphoma
Primary: Objective Response Rate — 25.8 percentage of participants
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Hodgkin Disease · Peripheral T Cell Lymphoma
Primary: Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) — 93; 95; 85 Percentage of participants
Previously Untreated Peripheral T-cell Lymphoma
Primary: Complete Response Rate — 75 percentage of participants
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Participants
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Lymphoma, T-cell, Peripheral
Primary: Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)…
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Peripheral T-cell Lymphoma
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30…
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) and Recommended Dose (RD) — 9 ug/kg/day
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Lymphoma
Primary: 2-year Overall Survival Rate — 31 percentage of participants
Adult T-Cell Leukemia and Lymphoma (ATL) · Adult Peripheral T-Cell Lymphoma (PTCL)
Primary: Incidence of Dose-Limiting Toxicities (DLTs) — 1 participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Peripheral T-Cell Lymphoma
Primary: Number of Patients That Achieved a Complete Response or a Partial Response (PR) — 32 participants
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Peripheral T-cell Lymphoma
Primary: Response Rate Per Independent Central Review — 32 of Patients who Responded